Introduction {#s1}
============

For patients whose asthma is not controlled with low-to-moderate doses of inhaled corticosteroids (ICS), the preferred initial step-up option in asthma management guidelines is the addition of a long-acting β~2~-agonist (LABA), either as a fixed-dose combination (FDC) or *via* two separate inhalers, with further step-up options including an increased dose of ICS \[[@C1], [@C2]\]. Until 2011, the British Thoracic Society/Scottish Intercollegiate Network recommended ICS and LABA in either separate or combination inhalers \[[@C3]\]. However, previous research has shown that, for patients using separate ICS and LABA inhalers, problems with adherence can result in LABA monotherapy, which has been associated with an increased risk of death \[[@C4]\]. Despite this, there is little evidence or guidance in the literature regarding whether separate or combination inhalers are preferred or recommended.

For adolescents and adults, the addition of LABA to ICS therapy often provides better symptom control and less need for reliever therapy \[[@C5]--[@C7]\]. In randomised controlled trials, patients receiving LABA in combination with ICS experienced improved lung function and symptom control compared with patients receiving an increased ICS dose \[[@C6], [@C8]--[@C13]\]. Some of these trials assessed the effect of combination inhalers compared with separate inhalers, but few statistically significant differences were observed \[[@C12]\]. However, up to 95% of patients with asthma are not eligible for participation in randomised controlled trials because of smoking, comorbidities or lung function impairment \[[@C14]\]. Furthermore, recruited patients benefit from close follow-up during their participation in these trials, and adherence in these studies is therefore likely to be higher than in the general patient population \[[@C15], [@C16]\]. Observational studies have indeed suggested that combination inhalers improve adherence in real-life patients, which is likely to influence therapeutic outcomes \[[@C17], [@C18]\]. Moreover, we have previously shown that an increased dose of ICS is as effective as add-on LABA *via* FDC inhaler in a general population of patients with asthma \[[@C19]\].

Another variable that may affect outcomes is particle size. Previous randomised trials have often focused on fine-particle ICS (mass median aerodynamic diameter 2--5 μm), such as fluticasone and budesonide, whereas a substantial proportion of the general asthma patient population is prescribed extrafine-particle ICS. Extrafine-particle ICS (*e.g.* beclomethasone, mass median aerodynamic diameter ∼1 μm), exhibits significantly increased lung deposition compared with fine-particle ICS \[[@C20], [@C21]\]. Furthermore, real-life research has suggested that treatment with extrafine-particle ICS results in similar or superior asthma-related outcomes at lower prescribed doses compared with fine-particle ICS \[[@C22]--[@C25]\].

The objective of this retrospective matched cohort study was to evaluate the real-life effectiveness of step-up asthma therapy with LABA added to ICS (any particle size) *via* separate inhalers compared with either an increased dose of extrafine-particle ICS or with a fine-particle ICS/LABA FDC inhaler. Our hypothesis was that, for adolescent and adult patients with evidence of persistent uncontrolled asthma, step-up treatments with either increased extrafine-particle ICS or with fine-particle ICS/LABA FDC would be a superior alternative to ICS and LABA in separate inhalers.

Methods {#s2}
=======

Data source and patients {#s2a}
------------------------

This historical, matched cohort, comparative effectiveness study drew on two large UK databases: the General Practice Research Database (GPRD), which is now part of the Clinical Practice Research Datalink \[[@C26]\], and the Optimum Patient Care Research Database (OPCRD) (supplementary material) \[[@C27]\]. Both databases are well described and have previously been used for respiratory research. The Independent Scientific Advisory Committee approved the use of GPRD data for the purpose of this study, and the OPCRD was approved by Trent Multi-Centre Research Ethics Committee (current NHS HRA approval REC reference 15/EM/0150) for clinical research use. The study protocol was designed by an independent steering committee and approved by the Anonymised Data Ethics Protocols and Transparency Committee, which is the independent scientific advisory committee of Optimum Patient Care. This study was registered at [clinicaltrials.gov](http://clinicaltrials.gov/) (identifier NCT01697722).

Eligible patients (aged 12--80 years) had at least 2 years of continuous data within the study window: a 1-year baseline period before the index date to control for baseline confounders, and a 1-year outcome period following the index date during which primary and secondary outcome parameters were assessed. During the baseline year, patients had at least two prescriptions for asthma therapy, including at least one for ICS. Exclusion criteria included a recorded diagnosis of chronic obstructive pulmonary disease (COPD) or any chronic respiratory disease other than asthma, as well as a history of smoking for patients between 61 and 80 years of age. This age limit was chosen in order to minimise the inclusion of patients with COPD misdiagnosed as asthma, since the proportion of patients with airflow obstruction who also have COPD increases to ∼40% for patients aged 60--69 years and the diagnoses can be difficult to differentiate \[[@C28]--[@C30]\].

The index date was defined as the date ICS treatment was stepped up by one of the following three options: 1) ≥50% increase in ICS dose of extrafine-particle beclomethasone dipropionate (ICS step-up); 2) addition of LABA *via* FDC of fine-particle ICS and LABA with no change in ICS dose (ICS/LABA FDC); or 3) addition of LABA by separate inhaler, with no change in ICS drug substance, device type or daily ICS dose in beclomethasone equivalents (separate ICS+LABA). During the baseline period, patients in all cohorts were prescribed either fine-particle or extrafine-particle ICS. During the outcome period, patients in the ICS step-up cohort were prescribed extrafine-particle ICS, patients in the ICS/LABA FDC cohort received fine-particle ICS, and patients in the separate ICS+LABA cohort received either fine-particle or extrafine-particle ICS (supplementary material and table S2). The study period covered 14 years between January 1997 and January 2011.

Outcome measures {#s2b}
----------------

The primary effectiveness end-point was risk-domain asthma control, *i.e.* no hospital admission, no emergency department attendance, no general practice attendance for lower respiratory tract infections, and no oral corticosteroid prescriptions as previously described \[[@C23], [@C25]\]. Secondary end-points included the number of severe exacerbations, number of acute respiratory events and treatment stability ([table 1](#TB1){ref-type="table"}) \[[@C31], [@C32]\].

###### 

Study definitions: database-derived outcome measures and matching criteria

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Primary end-point**
   Risk-domain asthma control includes all of the following:
    1. No asthma-related^\#^ hospital attendance or admission, ED attendance, out-of-hours attendance, or outpatient hospital attendance, and
    2. No GP consultation for lower respiratory tract infection^¶^ with resultant antibiotic prescription^¶^, and
    3. No prescription for acute course of oral corticosteroids
  **Secondary end-points**
   Number of severe exacerbations**^+^**, defined as any of the following \[31\]:
    1. Asthma-related^\#^ hospital attendance or admission or ED attendance, or
    2. Acute course of oral corticosteroids
   Number of acute respiratory events, defined as any of the following:
    1. Asthma-related^\#^ hospital attendance or admission or ED attendance, or
    2. Acute course of oral corticosteroids, or
    3. GP consultation for lower respiratory tract infection^¶^
   Treatment stability, includes all of the following:
    1. Asthma control (primary end-point, see above) and
    2. No treatment change, defined additional therapy or change in therapy as
      a) Increased ICS dose (by ≥50%), or
      b) Use of additional therapy, such as LABA, LTRA or theophylline
   Matching criteria: patients were matched at the index prescription date by
    1. Sex (male/female)
    2. Age (±5 years)
    3. Last ICS daily dose prescribed before index date prescription (categorised as 1--50 μg/51--100 μg/101--200 μg/201--300 μg/301--400 μg/\>400 μg in extrafine beclomethasone equivalents^§^)
    4. Asthma control (defined as primary end-point) during baseline year (controlled/not controlled)
    5. Mean SABA daily dose during baseline year^ƒ^ (categorised as 0 μg/1--200 μg/201--400 μg/\>400 μg)
    6. Asthma consultation(s) without severe exacerbation (0/1/≥2)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ED: emergency department; GP: general practitioner; ICS: inhaled corticosteroid; LABA: long-acting β~2~-agonist; LTRA: leukotriene receptor antagonist; SABA: short-acting β~2~-agonist. ^\#^: defined as all events with a lower respiratory code, including all asthma codes and lower respiratory tract infection codes; ^¶^: identified as GP consultations with a code for lower respiratory tract infection Read code in the database; ^+^: hospital attendance/admission and/or an oral corticosteroid course within a 2-week window were considered as one exacerbation; ^§^: doses of budesonide and the large-particle beclomethasone (Clenil Modulite, Chiesi, Manchester, UK) were halved, and fluticasone doses of 250 μg and 500 μg were treated as equivalent to extrafine-particle beclomethasone 200 and 400 μg; ^ƒ^: SABA daily dose was defined as total prescribed SABA during baseline year divided by 365. Reproduced from \[19\] with permission from the publisher.

The total daily coverage of β~2~-agonist (short-acting β~2~-agonist (SABA)+LABA) was calculated as the dispensed amount divided by 365 and defining two puffs of SABA (albuterol 200 μg or terbutaline 500 μg) as lasting 4 h, and two puffs of LABA *via* pressurised metered-dose inhaler or one puff of LABA *via* dry powder inhaler as lasting 12 h.

Statistical analysis {#s2c}
--------------------

The statistical analysis plan was defined before data analysis, following *a priori* defined standard procedures of the research team. After patient selection (figure S1), an exploratory analysis was carried out for all baseline variables, and statistical analyses were carried out *via* primary and secondary effectiveness outcomes. The analysis of baseline data revealed clinical and statistically significant differences between cohorts. A matched cohort analysis was therefore carried out using demographic and clinical matching criteria, as outlined in [table 1](#TB1){ref-type="table"}. To maximise cohort sizes, a 1:2 matching was carried out between the extrafine-particle ICS step-up and the separate ICS+LABA cohorts on the one hand, and between the FDC fine-particle ICS/LABA and the separate ICS+LABA cohorts on the other hand. Summary statistics were used to describe all matched baseline and outcome variables, both for the combined patient group and separated into treatment groups. To reduce the possibility of selection bias, numerous potential confounding variables were assessed, including some that were identified during previous respiratory research from the research team: baseline differences between treatment cohorts (p\<0.10) were considered potentially important, as well as baseline variables that were predictive (p\<0.05) of each effectiveness outcome in multivariable analyses. Variables that met these criteria were examined for collinearity, as well as for clinical importance, to select those used as potential confounders in regression modelling of outcomes.

Two-way comparisons between cohorts, both baseline and outcome variables, were analysed by conditional logistic regression. The adjusted odds of achieving risk-domain asthma control were compared between treatment groups using conditional logistic regression models, with asthma control used as the dependent variable, and treatment and potential confounding factors as explanatory variables. Variables with p\<0.10 were included as potential confounding factors. The same method was employed to determine the adjusted odds of achieving treatment stability. The total number of severe exacerbations during the outcome period was compared between matched treatment groups using a conditional Poisson regression model, and exacerbation rate ratios were determined. The model used empirical standard errors for more robust confidence intervals, and adjustments were made for potential baseline confounders. Statistically significant results were defined as p\<0.05. Analyses were carried out using SPSS Statistics (version 19; IBM, Armonk, NY, USA), SAS (version 9.3; SAS Institute, Cary, NC, USA), and Microsoft Office Excel 2007 (Microsoft Corp. Redmond, WA, USA).

Results {#s3}
=======

Extrafine-particle ICS dose step-up compared with ICS and LABA in separate inhalers {#s3a}
-----------------------------------------------------------------------------------

Information on the unmatched patient population is available in the supplementary material and table S1. After patient selection (figure S1) and 1:2 matching there were 3232 patients in the extrafine ICS step-up cohort and 6464 patients in the separate ICS+LABA cohort ([table 2](#TB2){ref-type="table"}, table S2, supplementary material). The mean age was 42 years and 61% were female. The cohorts were well matched for asthma-related parameters, and statistically significant differences between cohorts were small ([table 2](#TB2){ref-type="table"}). The mean ICS dose prescribed on the index date for the extrafine ICS step-up cohort was approximately twice that for the separate ICS+LABA cohort (394 *versus* 194 μg·day^−1^; p\<0.001).

###### 

Baseline demographic and clinical characteristics for two two-way comparisons of a step-up in asthma therapy using an increased dose of extrafine-particle ICS or a fine-particle ICS/LABA combination inhaler, compared with add-on LABA in a separate inhaler

  **Characteristics**                                             **Extrafine ICS step-up**   **FDC fine-particle ICS/LABA**                
  -------------------------------------------------------------- --------------------------- -------------------------------- ------------- ---------------------
  **Subjects n**                                                            3232                           6464                   7529             15 058
  **Female^\#^**                                                         1959 (60.6)                   3918 (60.6)             4689 (62.3)       9378 (62.3)
  **Age at index date years**^\#^                                         42.4±16.4                     42.3±16.4               42.1±16.1        42.2±15.9\*
  **Smoking status^¶^**                                                                                                                     
   Current smoker                                                        625 (22.3)                 1165 (21.5)\*\*\*          1564 (22.7)    2992 (24.0)\*\*\*
   Ex-smoker                                                             503 (18.0)                     956 (17.7)             1255 (18.2)       2190 (17.6)
   Nonsmoker                                                             1673 (59.7)                   3291 (60.8)             4076 (59.1)       7283 (58.4)
  **Nonsmokers aged 61--80** **years**                                   426 (13.2)                     826 (12.8)             878 (11.7)        1694 (11.2)
  **Risk-domain asthma control^\#^**                                     2094 (64.8)                   4188 (64.8)             4400 (58.4)       8800 (58.4)
  **Severe exacerbations**                                                                                                                  
   0                                                                     2412 (74.6)                  4745 (73.4)\*            5244 (69.7)   10 225 (67.9)\*\*\*
   1                                                                     573 (17.7)                    1175 (18.2)             1550 (20.6)       3186 (21.2)
   2                                                                      167 (5.2)                     378 (5.8)               499 (6.6)        1045 (6.9)
   ≥3                                                                     80 (2.5)                      166 (2.6)               236 (3.1)         602 (4.0)
  **Acute respiratory events**                                                                                                              
   0                                                                     2124 (65.7)                   4218 (65.3)             4522 (60.1)       8907 (59.2)
   1                                                                     701 (21.7)                    1391 (21.5)             1859 (24.7)       3725 (24.7)
   2                                                                      267 (8.3)                     560 (8.7)               731 (9.7)        1473 (9.8)
   ≥3                                                                     140 (4.3)                     295 (4.6)               417 (5.5)         953 (6.3)
  **Mean daily SABA dose^\#^**                                                                                                              
   0 μg·day^−1^                                                           131 (4.1)                     262 (4.1)               208 (2.8)         416 (2.8)
   1--200 μg·day^−1^                                                     1318 (40.8)                   2636 (40.8)             2563 (34.0)       5126 (34.0)
   201--400 μg·day^−1^                                                   814 (25.2)                    1628 (25.2)             2022 (26.9)       4044 (26.9)
   \>400 μg·day^−1^                                                      969 (30.0)                    1938 (30.0)             2736 (36.3)       5472 (36.3)
  **Last ICS dose before index date μg**·**day**^−1**^\#,+^**^             193±49                      194±54\*\*\*              295±187          293±185\*
  **ICS dose at index date μ**·**day**^−1^                                 394±98                      194±53\*\*\*              301±194        292±184\*\*\*
  **Asthma consultations/severe exacerbations^\#^**                                                                                         
   0                                                                     1157 (35.8)                   2314 (35.8)             2351 (31.2)      4702 (31.2)\*
   1                                                                     1136 (35.1)                   2272 (35.1)             2542 (33.8)       5084 (33.8)
   2                                                                     629 (19.5)                 1126 (17.4)\*\*\*          1603 (21.3)       3048 (20.2)
   ≥3                                                                     310 (9.6)                     752 (11.6)             1033 (13.7)       2224 (14.8)

Data are presented as n (%) or mean±[sd]{.smallcaps}, unless otherwise stated. Additional baseline data can be found in table S2. ICS: inhaled corticosteroids; LABA: long-acting β~2~-agonist; FDC: fixed-dose combination; SABA: short-acting β~2~-agonist.^\#^: matching variable; ^¶^: data were available for 2801 (86.7%) and 5412 (83.7%) patients in the ICS and separate ICS+LABA cohorts, respectively, and for 6895 (91.6%) and 12 465 (82.8%) in the ICS/LABA combination and separate ICS+LABA cohorts, respectively; ^+^: for the purposes of matching, doses of budesonide and large-particle beclomethasone (Clenil Modulite, Chiesi) were halved, and 250 and 500 μg of fluticasone were set to be equivalent to 200 and 400 μg of extrafine beclomethasone, respectively. At the index date, ICS doses are reported as half budesonide doses, while extrafine beclomethasone and fluticasone doses are reported without modification. \*: p≤0.05, \*\*\*p\<0.001, conditional logistic regression for two-way comparison between cohorts.

Over the outcome year, the proportion of patients who achieved risk-domain asthma control increased from 65% during the baseline year to 75% and 71% in the extrafine ICS step-up and separate ICS+LABA cohorts, respectively. Therefore, a significantly higher proportion of patients prescribed extrafine ICS step-up achieved risk-domain asthma control compared with those prescribed separate ICS+LABA, and fewer of these patients experienced severe asthma exacerbations or acute respiratory events or required a change in therapy ([table 3](#TB3){ref-type="table"}). The adjusted odds ratios for achieving risk-domain asthma control and treatment stability were significantly greater with extrafine ICS step-up compared with separate ICS+LABA. For risk-domain asthma control, the OR (95% CI) was 1.25 (1.13--1.38), while the rates of severe exacerbations or acute respiratory events were significantly lower ([figure 1](#F1){ref-type="fig"}).

###### 

Results from the 1-year outcome period from matched cohorts comparing a step-up in asthma therapy, using either an increased dose of extrafine-particle ICS, or a fine-particle ICS/LABA combination inhaler *versus* the addition of LABA to ICS in a separate inhaler

  **Outcome**                                     **Extrafine ICS step-up**    **p-value^ƒ^**    **FDC fine-particle ICS**    **p-value^ƒ^**                       
  ---------------------------------------------- --------------------------- ------------------ --------------------------- ------------------- ------------------ ---------
  **Subjects n**                                            3232                    6464                                           7529               15 058       
  **Risk-domain asthma control**                         2436 (75.4)            4573 (70.7)               \<0.001               5408 (71.8)       10 170 (67.5)     \<0.001
  **Severe exacerbation**                                                                                                                                          
   0                                                     2692 (83.3)            5101 (78.9)               \<0.001               6110 (81.2)       11 441 (76.0)     \<0.001
   1                                                     393 (12.2)              925 (14.3)                                     971 (12.9)         2313 (15.4)     
   2                                                      85 (2.6)               259 (4.0)                                       268 (3.6)          726 (4.8)      
   ≥3                                                     62 (1.9)               179 (2.8)                                       180 (2.4)          578 (3.8)      
  **Acute respiratory events**                                                                                                                                     
   0                                                     2464 (76.2)            4656 (72.0)               \<0.001               5495 (73.0)       10 350 (68.7)     \<0.001
   1                                                     528 (16.3)             1196 (18.5)                                     1343 (17.8)        2939 (19.5)     
   2                                                      143 (4.4)              355 (5.5)                                       404 (5.4)          976 (6.5)      
   ≥3                                                     97 (3.0)               257 (4.0)                                       287 (3.8)          793 (5.3)      
  **Treatment stability**                                2111 (65.3)            3487 (53.9)               \<0.001               4626 (61.4)        7862 (52.2)      \<0.001
  **≥1 asthma-related hospital attendance**               10 (0.3)                50 (0.8)                 0.008                 29 (0.4)            82 (0.5)        0.11
  **≥1 antibiotic prescriptions for LRTI**               387 (12.0)              815 (12.6)                0.56                 1050 (13.9)        2063 (13.7)       0.99
  **≥1 prescription for oral corticosteroids**           530 (16.4)             1343 (20.8)               \<0.001               1385 (18.4)        3557 (23.6)      \<0.001
  **Treatment change^\#^**                               589 (18.2)             1814 (28.1)               \<0.001               1433 (19.0)        4087 (27.1)      \<0.001
   Increase in ICS dose^¶^                                98 (3.0)              1294 (20.0)               \<0.001               1141 (15.2)        2445 (16.2)       0.034
   Additional therapy                                    581 (18.0)             1385 (21.4)               \<0.001                469 (6.2)         3344 (22.2)      \<0.001
  **ICS dose exposure μg**·**day**^−1¶^                274 (164--438)          155 (65--247)              \<0.001             197 (115--345)      192 (96--329)      0.008
  **Daily SABA dose μg**·**day**^−1^                   219 (110--548)          219 (110--438)             \<0.001             219 (110--438)      274 (110--548)    \<0.001
  **Daily β~2~-agonist coverage h^+^**                 3.3 (1.1--7.7)         10.4 (5.1--19.1)            \<0.001            19.3 (10.5--28.7)   11.8 (5.9--20.3)   \<0.001
   Change from baseline h                              0.6 (−0.5--2.3)        7.0 (2.9--14.7)             \<0.001            15.2 (7.4--23.7)    7.6 (2.9--15.2)    \<0.001
  **Spacer device prescribed**                           486 (15.0)             1182 (18.3)               \<0.001               985 (13.1)         2926 (19.4)      \<0.001
  **Oropharyngeal candidiasis^§^**                        155 (4.8)              321 (5.0)                 0.72                  396 (5.3)          819 (5.4)        0.57

Data are presented as n (%) or median (interquartile range), unless otherwise stated. ICS: inhaled corticosteroids; LABA: long-acting β~2~-agonist; FDC: fixed-dose combination; LRTI: lower respiratory tract infection; SABA: short-acting β~2~-agonist. ^\#^: patients could have more than one change in therapy (and both increased ICS dose and additional therapy) during the year. Additional therapy could include combination ICS/LABA inhaler (for ICS step-up cohort), separate LABA inhaler, leukotriene receptor antagonist and theophylline; ^¶^: the dose of budesonide was halved for equivalence with extrafine beclomethasone and fluticasone, for which actual doses were used in the analyses. Daily ICS dose exposure was calculated as the dispensed amount divided by 365. In the separate ICS+LABA cohort, 9--10% of patients were prescribed extrafine beclomethasone during the baseline period and 10--11% during the outcome period; ^+^: defined as the dispensed amount divided by 365 and defining two puffs of SABA as lasting 4 h, and two puffs of LABA *via* pressurised metered-dose inhaler or one puff of LABA *via* dry powder inhaler as lasting 12 h; ^§^: diagnosis of or therapy for oropharyngeal candidiasis (thrush); : p-value for conditional logistic regression.

![Adjusted outcome measures comparing a step-up in asthma therapy using an increased dose of extrafine-particle inhaled corticosteroids (ICS) *versus* the addition of a long-acting β~2~-agonist (LABA) to ICS in a separate inhaler. Data show the adjusted odds ratio (OR) or rate ratio (RR) with 95% CI. Variables have been adjusted for the following. ^\#^: number of oral corticosteroid prescriptions; ^¶^: smoking status and number of oral corticosteroid prescriptions; ^+^: smoking status and number of severe exacerbations during baseline year; ^§^: smoking status, number of oral corticosteroid prescriptions and number of primary care consultations.](00106-2015.01){#F1}

The daily dose of SABA during the outcome year was significantly higher in the extrafine ICS step-up cohort than in the separate ICS+LABA cohort, although the median was the same (219 μg·day^−1^). However, total β~2~-agonist coverage was significantly longer for the separate ICS+LABA cohort than for the extrafine ICS step-up cohort ([table 3](#TB3){ref-type="table"}, [figure 2a](#F2){ref-type="fig"}).

![Comparison of total β~2~-agonist coverage for patients prescribed a) an increased dose of extrafine inhaled corticosteroids (ICS) *versus* ICS+long-acting β~2~-agonist (LABA) in separate inhalers or b) fixed-dose combination (FDC) of fine-particle ICS/LABA inhalers *versus* ICS+LABA in separate inhalers. Data are presented as coverage in hours per 24 h, where the total daily coverage of β~2~-agonist (short-acting β~2~-agonist (SABA)+LABA) was calculated as the annual dispensed amount divided by 365 and two puffs of SABA (albuterol 200 μg or terbutaline 500 μg) were defined as lasting 4 h, and two puffs of LABA *via* pressurised metered-dose inhaler or one puff of LABA *via* dry powder inhaler were defined as lasting 12 h.](00106-2015.02){#F2}

Fine-particle ICS/LABA combination inhaler compared with ICS and LABA in separate inhalers {#s3b}
------------------------------------------------------------------------------------------

After matching, there were 7529 patients in the fine-particle ICS/LABA combination cohort and 15 058 patients in the separate ICS+LABA cohort. Most of the baseline differences between cohorts were small, although several were statistically significant because of the large cohort sizes ([table 2](#TB2){ref-type="table"}, table S2, supplementary material). For the patients who received separate ICS+LABA inhalers, the mean index date was 2 years earlier than for those who received fine-particle ICS/LABA FDC inhalers. Probably as a consequence of this, fewer patients in the separate ICS+LABA cohort had recorded smoking data (83% *versus* 92% in the ICS/LABA FDC cohort) ([table 2](#TB2){ref-type="table"}).

During the outcome year, the proportion of patients who achieved risk-domain asthma control increased from 58% during the baseline year to 72% in the fine-particle ICS/LABA cohort and 68% in the separate ICS+LABA cohort. Risk-domain asthma control and treatment stability were significantly higher for patients who received fine-particle ICS/LABA inhalers compared with separate ICS+LABA inhalers. For risk-domain asthma control, the OR (95% CI) was 1.06 (1.05--1.09) and the risk of severe exacerbations and acute respiratory events was significantly lower ([figure 3](#F3){ref-type="fig"}, [table 3](#TB3){ref-type="table"}). The proportion of patients changing treatment was also lower in the fine-particle ICS/LABA FDC cohort than in the separate ICS+LABA cohort ([table 3](#TB3){ref-type="table"}).

![Adjusted outcome measures comparing a step-up in asthma therapy using a fixed-dose combination (FDC) inhaler containing fine-particle inhaled corticosteroid (ICS)/long-acting β~2~-agonist (LABA) *versus* the addition of LABA to ICS in a separate inhaler. Data show the adjusted odds ratio (OR) or rate ratio (RR) with 95% CI. Variables have been adjusted for the following. ^\#^: smoking status, number of primary care consultations and medication possession ratio; ^¶^: smoking status, adherence to ICS therapy, number of nonasthma-related consultations and number of acute respiratory events; ^+^: number of acute respiratory events (categorised) and year of index date; ^§^: number of acute respiratory events (categorised), year of index date and number of primary care consultations.](00106-2015.03){#F3}

The daily dose of SABA was significantly lower, and the daily β~2~-agonist coverage (SABA+LABA) was significantly higher, for the fine-particle ICS/LABA FDC cohort compared with the separate ICS+LABA cohort ([table 3](#TB3){ref-type="table"}, [figure 2b](#F2){ref-type="fig"}).

Discussion {#s4}
==========

This study of a real-life patient population showed that the odds of achieving risk-domain asthma control and treatment stability were significantly higher with an increased dose of extrafine-particle ICS or with fine-particle ICS/LABA FDC inhalers, as compared with ICS and LABA *via* separate inhalers. Furthermore, the rates of severe exacerbations and acute respiratory events were significantly lower with increased doses of extrafine-particle ICS or fine-particle ICS/LABA FDC inhalers than with separate ICS+LABA inhalers. The total β~2~-agonist coverage (adding hours covered by SABA+LABA) was significantly longer for patients prescribed add-on LABA.

National and international guidelines recommend add-on LABA as the first step-up of asthma therapy. Until 2011 (the last year of our study period) the recommendation of British guidelines for add-on LABA was either *via* ICS/LABA FDC inhaler or ICS+LABA *via* separate inhalers \[[@C3], [@C33]\]. In agreement with this, add-on LABA was the most commonly prescribed step-up therapy in the current study. Of the 35 356 patients in the unmatched cohorts who met the eligibility criteria, 84% were prescribed add-on LABA, of whom more than two-thirds received ICS and LABA in separate inhalers.

Asthma management guidelines are often predominantly based on randomised controlled trials that exclude a large proportion of patients. Although the data are not always clear, several reports have suggested that there is no difference in efficacy between add-on LABA in combination or in separate inhalers \[[@C16], [@C33], [@C34]\]. This could partly be due to generally high adherence in these studies, which may therefore not reflect the situation in the general patient population of asthma patients, where adherence tends to be relatively low \[[@C15], [@C35], [@C36]\]. Differences in adherence probably contribute to the discrepancy between the efficacy shown in controlled trials and the effectiveness observed in real-life studies \[[@C19], [@C37], [@C38]\]. Real-life studies have indeed suggested that FDC inhalers can make a substantial contribution to aid refill persistence \[[@C18]\], and that patients on these inhalers are less likely to require rescue medication than those using separate inhalers \[[@C17]\]. Indeed, the current results show a substantial advantage of fine-particle ICS/LABA FDC inhalers compared with separate inhalers.

An alternative step-up option to add-on LABA is an increased dose of ICS, which has previously been associated with a reduction in serious adverse events and hospitalisation \[[@C39]\]. Our previous historical matched cohort study has shown that, in a general population of patients with asthma, an increased dose of extrafine-particle ICS is as effective as fine-particle ICS/LABA in a FDC inhaler \[[@C19]\]. Furthermore, the current study shows that an increased dose of extrafine ICS is significantly more effective than add-on LABA *via* separate inhalers. A potential concern of ICS step-up might be that this leads to increased use of reliever therapy. Although the statistical test shows that the daily dose of SABA was higher for patients prescribed increased extrafine ICS compared with those prescribed separate ICS+LABA, the median daily SABA dose was the same in both cohorts, suggesting that there is no real clinical difference between the groups. In contrast, the median daily SABA dose was substantially higher for patients prescribed separate ICS+LABA than for those prescribed fine-particle ICS/LABA in FDC inhalers (274 and 219 μg·day^−1^, respectively). Furthermore, for total β~2~-agonist coverage (SABA+LABA), the exposure was significantly longer for patients prescribed add-on LABA (median 3 h in the ICS step-up *versus* 10--19 h in the add-on LABA cohorts). Therefore, an ICS dose step-up does not appear to result in any substantial increase in SABA prescription, while total β~2~-agonist exposure increases substantially with add-on LABA.

In randomised controlled trials of bronchodilators, the primary end-point tends to be lung function, and patients generally have to demonstrate β~2~-agonist reversibility to be included. The trials are also often limited in timescale, and most require patients with stable asthma whose exacerbation risk is low. In this context, the current study has several strengths. The findings depict clinically relevant real-life outcomes for asthma therapy in UK primary care, the patient group is larger than most controlled trials, and the 1-year follow-up is likely to minimise seasonal variation and capture less frequent outcomes, such as exacerbations. We did not exclude active smokers (15--24% of each cohort, except in the 61--80-year-old age group), patients did not have to demonstrate β~2~-agonist reversibility to be included, and ∼25% of patients in each cohort had rhinitis, which is a risk factor for poor asthma control \[[@C40]\]. Therefore, the analysed patient group appears to be representative of the general UK asthma population, and this improves generalisability of the study findings to general practice.

Our primary end-point of risk-domain asthma control was designed to capture the absence of asthma exacerbations during the outcome year. This composite data outcome has been used in previous research \[[@C19], [@C24]\] and is in line with factors identified by expert working groups as being reflective of the future risk component of asthma control \[[@C31], [@C32], [@C41]\]. Although we conducted a matched cohort analysis, and confounding was eliminated to the greatest possible extent with adjusted analyses, we acknowledge that the use of matching may increase the risk of selection bias \[[@C42]\], and ignoring the matching variables may produce a certain population causal effect \[[@C43]\]. Similar to other historical cohort studies, this one is also limited by the fact that causal relationships cannot be inferred from the observed associations, and the possibility of unrecognised confounding factors remains. Nevertheless, we believe that, although slight baseline differences might still be present, they are unlikely to be of clinical significance.

For patients receiving ICS and LABA in separate inhalers, poor adherence to the ICS component can be associated with risks. An investigation into asthma deaths in the UK found that 6% of patients prescribed LABA in separate inhalers were not prescribed any ICS throughout the year, and an additional 12% had significant gaps in ICS prescribing, suggesting that approximately one in five of these patients were exposed to the increased risks associated with LABA monotherapy \[[@C3], [@C4]\]. In clinical practice, it is generally considered that combination inhalers improve adherence, and they guarantee that LABA is not taken without ICS \[[@C2]\]. Our results provide real-life evidence to support the notion that either ICS step-up or add-on LABA *via* FDC inhalers is more effective than ICS and LABA in separate inhalers, which is the least desirable step-up option in a general patient population. The importance of this information is emphasised by the fact that more than two-thirds of patients prescribed add-on LABA received it *via* separate inhalers.

In conclusion, this real-life study of a broad general population of young people and adults with persistent asthma suggests that step-up therapy, by increasing the dose of extrafine-particle ICS or by adding LABA in FDC inhalers, is a better approach than prescribing ICS and LABA in separate inhalers. Whether this is a strategy that will work better in some patient subgroups, *e.g.* patients with impaired therapeutic response to β~2~-agonists or those with frequent exacerbations, is a question for further study.
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